DiaMedica Therapeutics Inc.
DMAC
$5.80
$0.193.39%
| Weiss Ratings | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.01 | |||
| Price History | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.60% | |||
| 30-Day Total Return | -2.52% | |||
| 60-Day Total Return | 6.81% | |||
| 90-Day Total Return | 34.26% | |||
| Year to Date Total Return | 5.26% | |||
| 1-Year Total Return | 100.69% | |||
| 2-Year Total Return | 233.33% | |||
| 3-Year Total Return | 151.08% | |||
| 5-Year Total Return | 61.11% | |||
| 52-Week High % Change | -17.72% | |||
| 52-Week Low % Change | 162.15% | |||
| Price | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.82 | |||
| 52-Week Low Price | $2.14 | |||
| 52-Week Low Price (Date) | Jun 24, 2024 | |||
| 52-Week High Price (Date) | Feb 19, 2025 | |||
| Valuation | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 239.89M | |||
| Enterprise Value | 190.05M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.55 | |||
| Earnings Per Share Growth | -11.25% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 5.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $5.80 | |||
| Enterprise Value/EBITDA (TTM) | -7.89 | |||
| Enterprise Value/EBIT | -7.88 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 42.75M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 763 496 5454 | |||
| Address | 301 Carlson Parkway Minneapolis, MN 55305 | |||
| Website | www.diamedica.com | |||
| Country | United States | |||
| Year Founded | 2000 | |||
| Profitability | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -27.23% | |||
| Return on Equity | -- | |||
| Income Statement | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -24.07M | |||
| EBIT (TTM) | -24.11M | |||
| Net Income (TTM) | -21.71M | |||
| Net Income Avl. to Common (TTM) | -21.71M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -40.33% | |||
| EPS Diluted (TTM) | -0.55 | |||
| EPS Diluted Growth (Q YOY) | -24.62% | |||
| Balance Sheet | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 50.20M | |||
| Cash Per Share (Q) | $1.17 | |||
| Total Current Assets (Q) | 50.77M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 47.96M | |||
| Current Ratio (Q) | 11.815 | |||
| Book Value Per Share (Q) | $1.12 | |||
| Total Assets (Q) | 52.52M | |||
| Total Current Liabilities (Q) | 4.30M | |||
| Total Debt (Q) | 365.00K | |||
| Total Liabilities (Q) | 4.56M | |||
| Total Common Equity (Q) | 47.96M | |||
| Cash Flow | DMAC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 9.48M | |||
| Cash from Financing (TTM) | 11.87M | |||
| Net Change in Cash (TTM) | 1.90M | |||
| Levered Free Cash Flow (TTM) | -10.15M | |||
| Cash from Operations (TTM) | -19.45M | |||
